Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Burosumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ultragenyx Sells Future Crysvita Royalties For $400 Million
    Ultragenyx Sells Future Crysvita Royalties For $400 Million

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180804/20739/en/Ultragenyx-Announces-Sale-of-a-Portion-of-Future-North-American-Royalties-on-Crysvita-burosumab-for-400-Million-to-OMERS-Life-Sciences.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Kyowa Kirin’s Biologics Crysvita Receives Suppl Approval in US
    Kyowa Kirin’s Biologics Crysvita Receives Suppl Approval in US

    28 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761068

    FDA
    28 Aug 2025
    Share Share
    Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA
    Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA

    29 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231128306616/en

    BUSINESSWIRE
    29 Nov 2023
    Share Share
    Kyowa Kirin brings rare disease drug's marketing back in house, future US growth
    Kyowa Kirin brings rare disease drug's marketing back in house, future US growth

    03 May 2023

    // Beth Snyder Bulik ENDPTS

    https://endpts.com/kyowa-kirin-brings-rare-disease-drugs-marketing-back-in-house-plots-future-us-growth/

    Beth Snyder Bulik ENDPTS
    03 May 2023
    Share Share
    Ultragenyx Announces Sale of Portion of Future N. American Royalties on Crysvita
    Ultragenyx Announces Sale of Portion of Future N. American Royalties on Crysvita

    14 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/14/2479715/20739/en/Ultragenyx-Announces-Sale-of-a-Portion-of-Future-North-American-Royalties-on-Crysvita-burosumab-for-500-Million-to-OMERS-Capital-Markets.html

    GLOBENEWSWIRE
    14 Jul 2022
    Share Share
    Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA for TIO
    Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA for TIO

    24 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220624005247/en

    BUSINESSWIRE
    24 Jun 2022
    Share Share